Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 7/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 4/20 | 0.38 |
| ▸ | MMP9 | P14780 | 4/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4900643 | 0.97 | KDM4E (0.44) | KDM4EALDH1A1PKMPOLBHCRTR2 | |
| SCHEMBL4906561 | 0.92 | ALDH1A1 (0.44) | KDM4EALDH1A1PKMHCRTR2NR3C1 | |
| SCHEMBL4906844 | 0.90 | POLB (0.41) | POLBMMP2MMP9 | |
| SCHEMBL4902550 | 0.90 | TRPM8 (0.38) | KDM4EALDH1A1PKMHCRTR2TRPM8 | |
| SCHEMBL4905300 | 0.89 | POLB (0.43) | ALDH1A1POLBMMP9MMP1 | |
| SCHEMBL4904399 | 0.89 | ALDH1A1 (0.46) | KDM4EALDH1A1PKMHCRTR2TRPM8 | |
| SCHEMBL4905969 | 0.89 | POLB (0.43) | KDM4EALDH1A1POLBNR3C1 | |
| SCHEMBL4903896 | 0.89 | LMNA (0.46) | ALDH1A1POLBMMP9MMP1 | |
| SCHEMBL4898271 | 0.89 | POLB (0.44) | ALDH1A1POLBNR3C1MMP9MMP1 | |
| SCHEMBL4894435 | 0.89 | POLB (0.52) | ALDH1A1POLBMMP9MMP1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | KDM4E 3834/4885ALDH1A1 2956/4885PKM 861/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | KDM4E 3834/4885ALDH1A1 2956/4885PKM 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.